Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma

Moderna and Merck have developed a personalized mRNA vaccine that demonstrates significant promise in preventing the recurrence of melanoma. Results from a large, late-stage trial indicate that the treatment successfully reduced recurrence rates for the deadliest form of skin cancer. This achievement revives expectations for mRNA technology in oncology, highlighting its potential to transform cancer treatment. The collaboration between the two pharmaceutical companies marks a critical step forward in utilizing personalized medicine to combat advanced melanoma.